Modality
Cell Therapy
MOA
CGRPant
Target
CD123
Pathway
Ferroptosis
CML
Development Pipeline
Preclinical
May 2025
→ Nov 2025
PreclinicalCurrent
NCT06875000
2,511 pts·CML
2025-05→2025-11·Recruiting
2,511 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-174mo agoInterim· CML
Trial Timeline
Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2025-11-17 · 4mo ago
CML
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06875000 | Preclinical | CML | Recruiting | 2511 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 |